Analyst firms · Morgan Stanley · ARQT
Morgan Stanley ARQT price target and rating history
Arcutis Biotherapeutics Inc. (ARQT) · Health Care
Morgan Stanley rates Arcutis Biotherapeutics Inc. (ARQT) Overweight with a $37 price target, as of its latest action on Mar 2, 2022. It has published 3 rating actions on ARQT since July 2021, including 0 upgrades and 0 downgrades.
- Current rating
- Overweight
- Price target
- $37
- Median target, all firms
- Too few
- Actions on ARQT
- 3
Morgan Stanley price target on ARQT
Every Morgan Stanley rating on ARQT
- Mar 2, 2022
- Nov 19, 2021
- Jul 16, 2021
Questions about Morgan Stanley and ARQT
- What is Morgan Stanley's price target for ARQT?
- Morgan Stanley's latest stated price target for Arcutis Biotherapeutics Inc. (ARQT) is $37, from its action on Mar 2, 2022.
- What is Morgan Stanley's rating on ARQT?
- Morgan Stanley rates ARQT Overweight, a bullish rating, as of Mar 2, 2022.
- When did Morgan Stanley last change its view on ARQT?
- On Mar 2, 2022, Morgan Stanley raises its price target to $37 from $35, keeps Overweight.
More ARQT rating histories
All Morgan Stanley ratingsARQT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.